Exelixis, Inc. (NASDAQ:EXEL) Director George Poste Sells 11,686 Shares

Exelixis, Inc. (NASDAQ:EXEL) Director George Poste sold 11,686 shares of the stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $20.96, for a total transaction of $244,938.56. Following the completion of the sale, the director now directly owns 213,907 shares in the company, valued at approximately $4,483,490.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $21.00 on Thursday. The stock has a market capitalization of $6.37 billion, a price-to-earnings ratio of 32.81, a PEG ratio of 0.51 and a beta of 0.57. Exelixis, Inc. has a 1-year low of $18.64 and a 1-year high of $24.34. The company has a 50 day moving average price of $22.74 and a 200 day moving average price of $22.30.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.16). The company had revenue of $425.23 million for the quarter, compared to the consensus estimate of $461.04 million. Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The business’s revenue was up 4.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.12 earnings per share. On average, sell-side analysts expect that Exelixis, Inc. will post 1.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Stifel Nicolaus upped their target price on shares of Exelixis from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Friday, February 2nd. TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. Royal Bank of Canada boosted their price target on Exelixis from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Barclays lowered Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price target on the stock. in a report on Thursday, April 11th. Finally, William Blair restated an “outperform” rating on shares of Exelixis in a research note on Wednesday, May 1st. Seven analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.13.

Institutional Trading of Exelixis

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Fisher Asset Management LLC increased its position in shares of Exelixis by 232.6% in the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 728 shares in the last quarter. Contravisory Investment Management Inc. purchased a new position in Exelixis during the 4th quarter worth approximately $26,000. GAMMA Investing LLC acquired a new stake in Exelixis during the 4th quarter valued at $27,000. Rise Advisors LLC purchased a new stake in shares of Exelixis in the first quarter valued at $28,000. Finally, Fifth Third Bancorp lifted its holdings in shares of Exelixis by 44.2% in the third quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 604 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.